Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-controlled trial

Transplantation

Volumn 86, Issue 8, 2008, Pages 1043-1051

  Van Gelder, Teun ^a   Silva, Helio Tedesco ^b   De Fijter, Johan W ^c   Budde, Klemens ^d   Kuypers, Dirk ^e   Tyden, Gunnar ^f   Lohmus, Aleksander ^g   Sommerer, Claudia ^h   Hartmann, Anders ⁱ   Le Meur, Yann ^j   Oellerich, Michael ^k   Holt, David W ^l   Tönshoff, Burkhard ^m   Keown, Paul ⁿ   Campbell, Scott ^o   Mamelok, Richard D ^p  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f Karolinksa University   (Sweden)

^g Department of Nephrology ^*  (Estonia)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITY OF OSLO   (Norway)

^j DUPUYTREN UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY OF GÖTTINGEN   (Germany)

^l ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^m UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^o UNIVERSITY OF QUEENSLAND   (Australia)

^p Mamelok Consulting   (United States)

more..

Author keywords

Graft rejection; Mycophenolate mofetil; Therapeutic drug monitoring; Transplantation

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT FAILURE; WEIGHT REDUCTION; ADOLESCENT; CLINICAL PRACTICE; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; GRAFT REJECTION; HEALTH PERSONNEL ATTITUDE; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ATTITUDE OF HEALTH PERSONNEL; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 55949130835     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318186f98a     Document Type: Article

References (21)

1. Shaw LM, Korecka M, Venkataramana R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transpl 2003; 3: 534.
2. van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006; 17: 871.
3. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64: 672.
4. van Gelder T. Mycophenolate mofetil: How to further improve using an already successful drug? Am J Transpl 2005; 5: 199.
5. Bennett WM. Immunosuppression with mycophenolic acid: One size does not fit all. J Am Soc Nephrol 2003; 14: 2414.
6. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacyoforal mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261.
7. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German Study Group on Mycophenolate mofetil Therapy. J Am Soc Nephrol 2002; 13: 759.
8. Oellerich M, Shipkova M, Schultz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring. German Study Group on Mycophenolate mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 2000; 22: 20.
9. van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005; 80(2 Suppl): S244.
10. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: 145.
11. PawinskiT,HaleM,KoreckaM,et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48: 1497.
12. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monitor 2000; 22: 169.
13. Weber LT, Hoecker B, Armstrong VW, et al. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. Ther Drug Monitor 2006; 28: 623.
14. Holt DW, Johnston A. Monitoring immunosuppressive drugs: Has it a future? Ther Drug Monitor 2004; 26: 244.
15. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
16. Kiberd BA, LawenJ,Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004; 4: 1079.
17. Borrows R, Chusney G, Loucaidou M, et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: Association with acute rejection and toxicity. Am J Transplant 2006; 6: 121.
18. Hazzan M, Labalette M, Copin MC, et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: Results from a prospective, randomized trial. J Am Soc Nephrol 2005; 16: 2509.
19. van Hest R, Mathot R, Vulto A, et al. Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: A computer simulation. Ther Drug Monitor 2005; 27: 163.
20. LeMeur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improved patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496.
21. Marquet P. Clinical application of population pharmacokinetic methods developed for immunosuppressive drugs. Ther Drug Monit 2005; 27: 727.